$11.14 0.03 (+0.23%)
2/10/2012 4:00 PM

Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Featured Broker Partners


Advertisement